PF-03550096

From Wikipedia, the free encyclopedia
Jump to: navigation, search
PF-03550096
PF-03550096 structure.png
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C19H28N4O4
Molar mass 376.45 g/mol
3D model (Jmol)

PF-03550096 is a drug that acts as a potent agonist for the CB2 cannabinoid receptor, with good selectivity over CB1 having Ki values of 7nM at CB2 and 1500nM at CB1. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome,[1] but has only progressed to animal studies.[2]

See also[edit]

References[edit]

  1. ^ Ando K et al, BENZIMIDAZOLONE DERIVATIVES. WO 2008/032164
  2. ^ Kikuchi, A.; Ohashi, K.; Sugie, Y.; Sugimoto, H.; Omura, H. (2008). "Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity". Journal of pharmacological sciences. 106 (2): 219–224. doi:10.1254/jphs.FP0071599. PMID 18270474.